文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于PSMA-PET和MRI的原发性前列腺癌局部剂量递增放疗:非随机两臂2期试验(ARO2020-01)的计划安全性分析

PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-04-22

这项双中心2期非随机试验在25例/臂的中高危局限期前列腺癌患者中,将PSMA-PET用于定义前列腺内大体肿瘤体积并实施局部剂量递增放疗。6个月随访时两臂均未观察到3级毒性,泌尿生殖与胃肠道毒性、国际前列腺症状评分及生活质量评分较基线无显著差异。

要点

  • A臂局部剂量递增至75 Gy(20次),B臂近距离放疗19 Gy(1次)后外照射,均可行。
  • 两臂6个月随访均未观察到3级毒性。
  • 6个月时国际前列腺症状评分及生活质量评分较基线无显著差异。

核心结论

  • 这是首个前瞻性数据支持将PSMA-PET纳入根治性局部剂量递增放疗的可行性。
  • 患者6个月随访后维持良好生活质量且毒性低。

研究设计与样本

  • 双中心2期非随机两臂试验(HypoFocal,ARO2020-01),每臂入组25例中高危局限期原发性前列腺癌患者。
  • 患者经多参数磁共振成像和PSMA-PET分期,A臂接受局部剂量递增中度大分割放疗,B臂接受单次高剂量率近距离放疗后外照射。
  • PSMA-PET在原发性前列腺癌之外用于定义前列腺内大体肿瘤体积。
  • 毒性按不良事件通用术语标准(CTCAE)5.0版评估,并测量国际前列腺症状评分及欧洲癌症研究与治疗组织QLQ-PR25/-PR30生活质量问卷。

主要发现

  • PET信息实施后剂量递增的中位体积较大:A臂10.2 mL,B臂6.8 mL。
  • A臂所有患者剂量递增至75 Gy(20次)可行,B臂23例患者递增至19 Gy(1次)可行。
  • 两臂6个月随访时毒性、国际前列腺症状评分及欧洲癌症研究与治疗组织生活质量评分较基线均无显著差异。
  • 6个月随访时未观察到3级毒性。

临床怎么用

  • 作者认为该前瞻性数据支持将PSMA-PET纳入根治性局部剂量递增放疗的可行性。
  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The bicentric HypoFocal phase 2 trial investigates the implementation of molecular imaging with positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET) into modern focal dose-escalation radiation therapy (RT) concepts in 2 nonrandomized arms. We present the planned safety analysis after 6 months of follow-up. MATERIALS AND METHODS: Intermediate- and high-risk localized primary prostate cancer patients staged with multiparametric magnet resonance tomography and PSMA-PET were either treated with focal dose-escalated moderately hypofractionated RT (arm A) or single fraction high-dose-rate brachytherapy followed by external beam RT (arm B). PSMA-PET was used in addition to primary prostate cancer to define the intraprostatic gross tumor volume. Gastrointestinal and genitourinary toxicities were assessed according to Common Toxicity Criteria for Adverse Events (version 5.0) criteria. International Prostate Symptom Score was measured and quality of life assessed with European Organisation for Research and Treatment of Cancer questionnaires QLQ-PR25/-PR30. We enrolled 25 patients in each study arm. RESULTS: The implementation of PET-information led to large median volumes for dose escalation: 10.2 mL in arm A and 6.8 mL in Arm B. RT dose-escalation was feasible in all patients of arm A with up to 75 Gy (20 fractions) and in 23 patients with up to 19 Gy (1 fraction) in arm B. Toxicities, International Prostate Symptom Scores, and European Organisation for Research and Treatment of Cancer quality of life scores were not significantly different between baselines and 6 months follow-up in both arms. No grade 3 toxicities were observed at 6 months follow-up. CONCLUSIONS: This is the first prospective data supporting the feasibility of PSMA-PET-implementation into definitive focal dose-escalated RT. Patients maintained a good quality of life and a low toxicity profile after 6 months of follow-up.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zamboglou C, Spohn SKB, Ruf J, et al. PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). Int J Radiat Oncol Biol Phys. 2022. PMID: 35469897. doi:10.1016/j.ijrobp.2022.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。